The debt of CG Oncology, Inc. over the past 3 years
Chart CG Oncology, Inc.: liquid cash, total debt, net cash, fiscal 2023–2025 Open the chart →At the end of fiscal 2025, the latest fiscal year on file, CG Oncology, Inc. had liquid cash of $742.15M and total debt of $3M: net cash of $739.15M. It had more liquid cash than debt at all 3 year-ends shown. Total debt was highest at the end of fiscal 2025 ($3M) and lowest at the end of fiscal 2023 ($0).
Year by year
| Fiscal year | Liquid cash | Total debt* | Net cash* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $742.15M* | $3M | $739.15M |
| 2024ended Dec 31, 2024 | $742M* | $0 | $742M |
| 2023ended Dec 31, 2023 | $187.67M* | $0 | $187.67M |
Fiscal years as CG Oncology, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on CG Oncology, Inc.
- The revenue of CG Oncology, Inc.
- The profitability of CG Oncology, Inc.
- All of CG Oncology, Inc.'s financials, charted
Companies of a similar size
- ORAORMAT TECHNOLOGIES, INC.
- EXPEAGLE MATERIALS INC
- ANAUTONATION, INC.
- BXSLBlackstone Secured Lending Fund
- LAURLaureate Education, Inc.
Not investment advice. This page shows what CG Oncology, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.